Literature DB >> 30633361

Nanovaccine: A novel approach in immunization.

Seyed Mohammad Gheibi Hayat1, Majid Darroudi2.   

Abstract

Despite great advances in the field of vaccination, there are still needs for novel and effective vaccines because still no effective vaccines have been produced for some diseases such as malaria, acquired immune deficiency syndrome (AIDS), and tuberculosis. Furthermore, many of the existing vaccines have disadvantages such as failure to stimulate completely the immune system, in vivo instability, high toxicity, the need for cold chain, and multiple administrations. Nanotechnology has been raised as a powerful tool for solving these problems in this regard. Generally, nanovaccines are a new generation of vaccines using nanoparticles (NPs) as carriers and/or adjuvants. Due to the similar scale (size) between the NPs and pathogens, the immune system can be stimulated well, resulting in triggered cellular and humoral immunity responses. Other benefits of the nanovaccines include their better stability in blood flow to increase the shelf life in blood, enhanced immune system stimulation, no need for booster doses, no need to maintain the cold chain, and ability to create active targeting. In addition, nanovaccines have raised the hope to treat diseases such as rheumatoid arthritis, AIDS, malaria, and chronic autoimmune, and so forth.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  adjuvant; nanoparticle; nanovaccine; vaccine delivery

Year:  2019        PMID: 30633361     DOI: 10.1002/jcp.28120

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  15 in total

1.  Nanotechnology for the Development of Nanovaccines in Cancer Immunotherapy.

Authors:  Maria Aurora Grimaudo
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Nanotechnology based solutions for anti-leishmanial impediments: a detailed insight.

Authors:  Humzah Jamshaid; Fakhar Ud Din; Gul Majid Khan
Journal:  J Nanobiotechnology       Date:  2021-04-15       Impact factor: 10.435

Review 3.  Significant perspectives on various viral infections targeted antiviral drugs and vaccines including COVID-19 pandemicity.

Authors:  Gandarvakottai Senthilkumar Arumugam; Kannan Damodharan; Mukesh Doble; Sathiah Thennarasu
Journal:  Mol Biomed       Date:  2022-07-15

4.  Systemic Neutralizing Antibodies and Local Immune Responses Are Critical for the Control of SARS-CoV-2.

Authors:  Shaswath S Chandrasekar; Yashdeep Phanse; Mariah Riel; Rachel E Hildebrand; Mostafa Hanafy; Jorge E Osorio; Sherein S Abdelgayed; Adel M Talaat
Journal:  Viruses       Date:  2022-06-10       Impact factor: 5.818

Review 5.  Multimodality imaging of nanoparticle-based vaccines: Shedding light on immunology.

Authors:  Muhsin H Younis; Zhongmin Tang; Weibo Cai
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2022-05-02

6.  DNA nanovaccines prepared using LemA antigen protect Golden Syrian hamsters against Leptospira lethal infection.

Authors:  Thaís Larré Oliveira; Kátia Leston Bacelo; Karine Maciel Forster; Vinicius Ilha; Oscar Endrigo Rodrigues; Daiane D Hartwig
Journal:  Mem Inst Oswaldo Cruz       Date:  2020-04-17       Impact factor: 2.743

Review 7.  Nanodelivery of STING agonists against cancer and infectious diseases.

Authors:  Jiarong Zhou; Christian J Ventura; Ronnie H Fang; Liangfang Zhang
Journal:  Mol Aspects Med       Date:  2021-08-02

Review 8.  Emerging Advances of Nanotechnology in Drug and Vaccine Delivery against Viral Associated Respiratory Infectious Diseases (VARID).

Authors:  Amir Seyfoori; Mahdieh Shokrollahi Barough; Pooneh Mokarram; Mazaher Ahmadi; Parvaneh Mehrbod; Alireza Sheidary; Tayyebeh Madrakian; Mohammad Kiumarsi; Tavia Walsh; Kielan D McAlinden; Chandra C Ghosh; Pawan Sharma; Amir A Zeki; Saeid Ghavami; Mohsen Akbari
Journal:  Int J Mol Sci       Date:  2021-06-28       Impact factor: 5.923

9.  In Vivo Sustained Release of Peptide Vaccine Mediated by Dendritic Mesoporous Silica Nanocarriers.

Authors:  Weiteng An; Sira Defaus; David Andreu; Pilar Rivera-Gil
Journal:  Front Immunol       Date:  2021-06-16       Impact factor: 7.561

10.  Production of a Promising Biosynthetic Self-Assembled Nanoconjugate Vaccine against Klebsiella Pneumoniae Serotype O2 in a General Escherichia Coli Host.

Authors:  Zhehui Peng; Jun Wu; Kangfeng Wang; Xin Li; Peng Sun; Lulu Zhang; Jing Huang; Yan Liu; Xiaoting Hua; Yunsong Yu; Chao Pan; Hengliang Wang; Li Zhu
Journal:  Adv Sci (Weinh)       Date:  2021-05-24       Impact factor: 16.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.